A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic (IV) Non-Small-Cell Lung Cancer. (OSE2101C301)

Trial Profile

A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic (IV) Non-Small-Cell Lung Cancer. (OSE2101C301)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs OSE 2101 (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATALANTE-1
  • Sponsors OSE Immunotherapeutics; OSE Pharma
  • Most Recent Events

    • 02 Oct 2017 According to an OSE Immunotherapeutics media release, follow-up of patients is ongoing.
    • 07 Sep 2017 According to an OSE Immunotherapeutics media release, a complementory review of more mature clinical data will be conducted and decision will be made about the continuation of study in fourth quarter of 2017.
    • 16 Aug 2017 Last checked against European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top